Wrinkles

... AP Wire FTC approves Botox-maker Allergan's takeover of Inamed Subscriber Services Complete Forecast Search Recent News Archives Web for Jobs Cars Real Estate Apartments Local Shopping Find an Ad Dating News Sports Opinion / Letters Obituaries Business Jackson Columns Book of Lists Personal Finance Technology Entertainment Living Past Articles ONLINE EXTRAS Audio & Video Blogs Building Our City Discussion Boards Gardening 101 Newspaper Ads News To Use NIE S.C.

History Weddings Women's Expo SITE SERVICES Past Articles Contact Us Ad Rates (Download) How to Advertise Maps & Directions RSS Feeds Yellow Pages Back to Home > Wednesday, Mar 08, 2006 Business email this print this reprint or license this Posted on Wed, Mar.

08, 2006 FTC approves Botox-maker Allergan's takeover of Inamed ALEX VEIGA Associated Press LOS ANGELES - Federal antitrust regulators said Wednesday they approved Botox-maker Allergan Inc.'s $3.2 billion acquisition of Inamed Corp., citing an agreement with the companies to divest Inamed of its right to a potential rival to Botox.

The Federal Trade Commission voted 4-0 to clear the takeover.

A final order by the commission is expected to be issued after a 30-day public comment period.

Irvine-based Allergan said it expects to complete its exchange offer for the outstanding shares of Santa Barbara-ba...

... Bismarck Tribune Online - World and National News /* */ .headerx { border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: #CCCCCC; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#666666 } Article Search: Web Search: Mar 8, 3:51 PM EST FTC Approves Allergan Takeover of Inamed By ALEX VEIGA AP Business Writer LOS ANGELES (AP) - Federal antitrust regulators said Wednesday they approved Botox-maker Allergan Inc.'s $3.2 billion acquisition of Inamed Corp., citing an agreement with the companies to divest Inamed of its right to a potential rival to Botox.

The Federal Trade Commission voted 4-0 to clear the takeover.

A final order by the commission is expected to be issued after a 30-day public comment period.

Irvine-based Allergan said it expects to complete its exchange offer for the outstanding shares of Santa Barbara-based Inamed's common stock on Friday, the expiration date for the offer.

"We are pleased to have received U.S.

antitrust approval from the FTC, and we look forward to rapidly completing the Inamed acquisition so we can initiate our integration plan," David E.I.

Pyott, Allergan's chairman and chief executive, said in a statement.

The two cosmetic treatment product makers agreed to combine in December.

Botox is now the only botulinum toxin approved by the Food and Drug Administration to treat facial wrinkles.

The FTC concluded that Allergan's takeover of Inamed would reduce competition in the U.S.

mar...

... Stock Market News and Investment Information RSS (Adds detail, comment from Allergan) WASHINGTON, March 8 (Reuters) - U.S.

antitrust authorities said on Wednesday they had approved Allergan Inc.'s (AGN.N: Quote, Profile, Research) proposed $3.2 billion takeover of breast implant maker Inamed Corp.

(IMDC.O: Quote, Profile, Research) after the companies agreed to divest the rights to a wrinkle treatment that could compete with Allergan's Botox.

The Federal Trade Commission voted unanimously to approve the deal on the condition that Allergan and Inamed return the development rights of the treatment, Reloxin, to Ipsen Ltd., its British-based manufacturer.

The agency said the deal would have probably harmed consumers without the divestment because it would have removed Reloxin as an imminent competitor ...